Triple meeting 2025 – Halda’s proximity play in prostate
Early data with the RIPTAC HLD-0915 look competitive.
Private US biotechs head for human trials
Halda, Accent and Vividion take more projects into phase 1.
Early data with the RIPTAC HLD-0915 look competitive.
Halda, Accent and Vividion take more projects into phase 1.
